Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19

Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19

1. “Product Information. Agenerase (amprenavir).” Glaxo Wellcome, Research Triangle Pk, NC.

2. “Product Information. Crixivan (indinavir).” Merck & Co, Inc, West Point, PA.

3. “Product Information. Eliquis (apixaban).” Bristol-Myers Squibb Canada Inc, Montreal, IN.

4. “Product Information. Evotaz (atazanavir-cobicistat).” Bristol-Myers Squibb, Princeton, NJ.

5. “Product Information. Fortovase (saquinavir)” Roche Laboratories, Nutley, NJ.

6. “Product Information. Lexiva (fosamprenavir).” GlaxoSmithKline, Research Triangle Park, NC.

7. “Product Information. Norvir (ritonavir).” Abbott Pharmaceutical, Abbott Park, IL.

8. “Product Information. Prezista (darunavir).” Ortho Biotech Inc, Bridgewater, NJ.

9. “Product Information. Viracept (nelfinavir).” Agouron Pharma Inc, La Jolla, CA.

10. “Product Information. Xarelto (rivaroxaban).” Bayer Inc, Toronto, IA.

11. Баутин А. Е., Мазурок В. А., Осовских В. В., Афанасьева К. Ю. Гемодинамические эффекты маневра мобилизации альвеол у пациентов кардиохирургического профиля с систолической дисфункцией левого желудочка. Анестезиология и реаниматология. 2014; 59(6):43-8.

12. Временные методические рекомендации Минздрава России “Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID19)”, версия 4 от 27.03.2020.

13. A statement from the International Society of Hypertension on COVID-19. https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-onCOVID-19/

14. Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med. 2016 Jan-Feb;36(1):78-80. doi:10.5144/0256-4947.2016.78.

15. Alon D, Stein GY, Korenfeld R, Fuchs S. Predictors and outcomes of infection-related hospital admissions of heart failure patients. PLoS One. 2013 Aug 23;8(8):e72476. doi:10.1371/journal.pone.0072476. eCollection 2013.

16. Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020 Mar 19. doi:10.1001/jama.2020.4326. [Epub ahead of print].

17. ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak. ASEcho.org

18. AST Transplantation. COVID 19 Organ Donation and Transplant Town Hall. webinar was recorded on March 23, 2020: https://www.youtube.com/watch?v=LUM8-vDHkI&feature=youtu.be

19. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016 Aug;49:129-33. doi:10.1016/j.ijid.2016.06.015. Epub 2016 Jun 21.

20. Barnes M, Heywood AE, Mahimbo A, et al. Acute myocardial infarction and influenza: a meta-analysis of case-control studies. Heart. 2015;101(21):1738-47. doi:10.1136/heartjnl-2015-307691.

21. Brigham and Women’s Hospital COVID-19 Critical Care Clinical Guidelines. http://www.covidprotocols.org/

22. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801-9.

23. Brozovic M, Gurd LJ. Prothrombin during warfarin treatment. Br J Haematol. 1973;24:579-88.

24. BSE Clinical guidance regarding provision of echocardiography during the COVID-19 pandemic. www.bsecho.org

25. Cerner Multum, Inc. “Australian Product Information.” O 0

26. Cerner Multum, Inc. “UK Summary of Product Characteristics.” O 0

27. Cerner Multum, Inc. “UK Summary of Product Characteristics.” O 0

28. Chan JWM, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003;58:686-689.

29. Chen C, Zhou Y, Wang DW. ARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020; Mar 5. doi:10.1007/s00059-020-04909-z.

30. Chen C, Chen C, Yan JT et al. Analysis of myocardial injury in patients with COVID19 and association between concomitant cardiovascular diseases and severity of COVID-19. Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 6;48(0):E008. doi:10.3760/cma.j.cn112148-20200225-00123.

31. Choi AD, Abbara S, Branch KR, et al. SCCT Guidance for Use of Cardiac Computed Tomography Amidst the COVID-19 Pandemic. J Cardiovasc Comput Tomogr. 2016 Nov — Dec;10(6):435-49. doi:10.1016/j.jcct.2016.10.002.

32. Coronavirus: COVID-19 Information for transplant professionals. https://bts.org.uk/wp-content/uploads/2020/03/Coronavirus-transplant-information-25th-March-2020.pdf

33. Darlington MR. Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir. Ann Pharmacother. 1997 May;31(5):647.

34. Elkind MS, Harrington RA, Benjamin IJ. Role of the American Heart Association in the Global COVID-19 Pandemic. Circulation. 2020 Mar 17. doi:10.1161/CIRCULATIONAHA.120.046749. [Epub ahead of print].

35. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Mar 11. pii:S22132600(20)30116-8. doi:10.1016/S2213-2600(20)30116-8. [Epub ahead of print].

36. Ferrario CM, Jessup J, Gallagher PE, et al. Effects of renin-angiotensin system blockage on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int., 2005;68:2189-96.

37. Frederik GPW, Shah PB, Aronow HD, et al. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From ACC’s Interventional Council and SCAI. JACC, March 2020. doi:10.1016/j.jacc.2020.03.021.

38. Gao Y. Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19. J Med Virol. 2020 Mar 17. doi:10.1002/jmv.25770.

39. Gatti G, Alessandrini A, Camera M, et al. Influence of indinavir and ritonavir on warfarin anticoagulant activity. AIDS. 1998;12:825-6.

40. Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy. JAMA 2020. Published Online 13.03.2020. doi:10.1001/jama.2020.4031.

41. Guan W-j, Ni Z-y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New Eng J Med. February 28, 2020; doi:10.1056/NEJMoa2002032. [Epub ahead of print].

42. Hamblin TJ Interaction between warfarin and phenformin. Lancet. 1971 Dec 11;2(7737):1323. doi:10.1016/s0140-6736(71)90650-7.

43. Hansen RA, Tu W, Wang J, Ambuehl R, et al. Risk of adverse gastrointestinal events from inhaled corticosteroids. Pharmacotherapy 2008;28:1325-34. doi:10.1592/phco.28.11.1325.

44. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID19 https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-ahastatementaddresses-concerns-re-using-raas-antagonists-in-covid-19.

45. http://www.chinacdc.cn/en/COVID19.

46. http://www.covid19-druginteractions.org.

47. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.

48. https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/18016/donationinternationalreflections-17032020.pdf.

49. https://pubs.rsna.org/doi/pdf/10.1148/radiol.2020200847.

50. https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnpusein-covid19.

51. https://www.ema.europa.eu/en/documents/press-release/ema-gives-advice-use-nonsteroidalanti-inflammatories-covid-19_en.pdf.

52. https://www.heart.org/en/about-us/coronavirus-covid-19-resources, дата обращения 18.03.2020.

53. https://www.journalofcardiovascularct.com/article/S1934-5925(20)30125-8/pdf.

54. https://www.medrxiv.org/content/10.1101/2020.02.29.20027698v2, https://medium.com/@nigam/higher-co-infection-rates-in-covid19-b24965088333.

55. https://www.thelancet.com/action/showPdf?pii=S2213-2600%2820%2930120-X.

56. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020 Mar 16. pii: ehaa190. doi:10.1093/eurheartj/ehaa190. [Epub ahead of print].

57. Hui H, Zhang Y, Yang X, et al. Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia. Medrxiv.org, posted 27.02.2020. doi:10.1101/2020.02.24.20027052.

58. Hypertension Canada’s Statement on: Hypertension, ACE-Inhibitors and Angiotensin Receptor Blockers and COVID-19. https://hypertension.ca/wp-content/uploads/2020/03/2020-30-15-Hypertension-Canada-Statement-on-COVID-19-ACEi-ARB.pdf.

59. Itkonen MK, Tornio A, Lapatto-Reiniluoto O, et al. Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. Clin Pharmacol Ther. 2019 Jan;105(1):219-228. doi:10.1002/cpt.1099. Epub 2018 Aug 9.

60. Knoell KR, Young TL, Cousins ES. Potential interaction involving warfarin and ritonavir. Ann Pharmacother. 1998;32:1299-302. doi:10.1345/aph.17456

61. Koch-Weser J, Sellers EM. Drug interactions with coumarin anticoagulants (second of two parts). N Engl J Med. 1971;285:547-58. doi:10.1056/NEJM197109022851005

62. Ku LL, Ward CO, Durgin SJ. A clinical study of drug interaction and anticoagulant therapy. Drug Intell Clin Pharm. 1970;4:300-6.

63. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratoryconfirmed influenza infection. N Engl J Med. 2018 Jan 25;378(4):345-353. doi:10.1056/NEJMoa1702090.

64. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. March 10, 2020. doi:10.7326/M20-0504. [Epub ahead of print].

65. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol (2020). doi:10.1007/s00392-020-01626-9.

66. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020. Feb 7. doi:10.1097/CM9.0000000000000744.

67. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020 Mar;63(3):364-374. doi:10.1007/s11427-020-1643-8. Epub 2020 Feb 9.

68. Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19 The Lancet Infect Dis. 19, 2020. doi:10.1016/S1473-3099(20)30232-2.

69. Llibre JM, Romeu J, Lopez E, Sirera G “Severe interaction between ritonavir and acenocoumarol.” Ann Pharmacother 36 (2002):621-3. doi:10.1345/aph.19361.

70. Mahmud E. The Evolving Pandemic of COVID-19 and Interventional Cardiology. Position of President of Society for Cardiovascular Angiography & Interventions. www.scai.org,16.03.2020.

71. Marsousi N, Daali Y, Fontana P et al. Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites. Clin Pharmacokinet. 2018 Oct;57(10):1347-1354. doi:10.1007/s40262-018-0637-6.

72. Mehra MR, Ruschitzka F. COVID-19 Illness and Heart Failure: A Missing Link? JACC: Heart Failure. 2020: doi:10.1016/j.jchf.2020.03.004.

73. Moriarty LF, Plucinski MM, Marston BJ, et al. Public health responses to Covid-19 outbreaks on cruise ships — worldwide, February-March. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):347-52. doi:10.15585/mmwr.mm6912e3.

74. Newshan G, Tsang P. Ritonavir and warfarin interaction. AIDS. 1999;13:1788-9. doi:10.1097/00002030-199909100-00028.

75. Nguyen JL, Yang W, Ito K, et al. Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol. 2016 Jun 1;1(3):274-81. doi:10.1001/jamacardio.2016.0433.

76. NHSBT/BTS guidance for clinicians on consent for solid organ transplantation in adults and living organ donation in the context of the COVID-19 pandemic. https://bts.org.uk/wp-content/uploads/2020/03/NHSBT-BTS-consent-guidance-COVID-19-26.3.20.pdf.

77. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID19) in China [Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 17;41(2):145-151. doi:10.3760/cma.j.issn.0254-6450.2020.02.003. [Epub ahead of print]

78. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. March 23, 2020; doi:10.1001/jama.2020.4683. Published online.

79. Park JH, Balmain S, Berry C, et al. Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart. 2010 Apr;96(7):533-8. doi:10.1136/hrt.2009.175257.

80. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi:10.1002/ejhf.592. Epub 2016 May 20.

81. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang

82. Prescribing information. Brilinta (ticagrelor). Wilmington, DE: AstraZeneca LP, 07/2011.

83. Prioritisation of Heart Failure Service Provision During Covid-19. https://www.bsh.org.uk/2020/03/19/prioritisation-of-heart-failure-service-provision-during-covid-19.

84. Product monograph. Brilinta (ticagrelor). Mississauga, Ontario, Canada: AstraZeneca CanadaInc., May 2011.

85. Putot А, Chague F, Manckoundia P, on behalf of RICO Survey. Post-Infectious Myocardial Infarction: New Insights for Improved Screening. J Clin Med. 2019;8(6):827. doi:10.3390/jcm8060827.

86. Rivar MB, Bajwa EK, Januzzi JL, et al. Prognostic significance of elevated cardiac troponinT levels in acute respiratory distress syndrome patients. PLoS One. 2012;7(7):e40515. doi:10.1371/journal.pone.0040515.

87. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; Mar 3. doi:10.1007/s00134-020-05991-x.

88. Sandau KE, Funk M, Auerbach A, et al. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. Circulation. 2017 Nov 7;136(19):e273-e344. doi:10.1161/CIR.0000000000000527.

89. Sawamura A, Okumura T, Ito M, et al, Investigators CP. Prognostic value of electrocardiography in patients with fulminant myocarditis supported by percutaneous venoarterial extracorporeal membrane oxygenationanalysis from the CHANGE PUMP study. Circ J. 2018 Jul 25;82(8):2089-95. doi:10.1253/circj.CJ-18-0136.

90. Schumann J, Henrich EC, Strobl H, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2018 Jan 29;1:CD009669. doi:10.1002/14651858.CD009669.pub3.

91. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12 — March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-6. doi:10.15585/mmwr.mm6912e2.

92. Stading JA. Effects of prednisone on the International Normalized Ratio. Am J Health Syst Pharm. 2006;63:2354-6. doi:10.2146/ajhp060105

93. Statement of the European Society of Hypertension (ESH) on hypertension, Renin Angiotensin System blockers and COVID-19. https://www.eshonline.org/spotlights/esh-stabtement-on-covid-19.

94. Suzuki T, Koga H, Yamazaki S, et al. Probable interaction between warfarin and antitumor agents used in R-ESHAP chemotherapy. Clin Ther. 2008 Jun;30(6):1155-9. doi:10.1016/j.clinthera.2008.06.008.

95. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020 Mar 17. doi:10.1056/NEJMc2004973. [Epub ahead of print].

96. Veronese G, Ammirati E, Cipriani M, Frigerio M. Fulminant myocarditis: Characteristics, treatment, and outcomes. Anatol J Cardiol. 2018 Apr;19(4):279-286. doi:10.14744/AnatolJCardiol.2017.8170. Epub 2018 Mar 13.

97. Wadman B, Werner I. Thromboembolic complications during corticosteroid treatment of temporal arteritis. Lancet. 1972 Apr 22;1(7756):907. doi:10.1016/s0140-6736(72)90784-2.

98. Wakai A, McCabe A, Kidney R, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev. 2013 Aug 6;(8):CD005151. doi:10.1002/14651858.CD005151.pub2.

99. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA. 2020. doi:10.1001/jama.2020.1585.

100. Wang YH, Zhang GH, Zhang LL, et al. Adrenal hemorrhage in a patient with systemic lupus erythematosus. Beijing Da Xue Xue Bao Yi Xue Ban. 2019 Dec 18;51(6):1178-81.

101. Watkins J. Preventing a covid-19 pandemic. BMJ. 2020;m810. doi:10.1136/bmj.m810.

102. Weng C-L, Zhao Y-T, Liu Q-H, et al. Meta-analysis: noninvasive ventilation in acute cardiogenic pulmonary edema. Ann Intern Med. 2010 May 4;152(9):590-600. doi:10.7326/0003-4819-152-9-201005040-00009.

103. WHO Coronavirus disease 2019 (COVID-19). Situation Report–41. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200301-sitrep-41-covid-19.pdf?sfvrsn=6768306d_2.

104. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID19). Geneva: WHO; 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/whochina-joint-mission-on-covid-19-final-report.pdf]

105. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. Published online February 24, 2020. doi:10.1001/jama.2020.2648.

106. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications European Heart Journal. Published online 18 March 2020. doi:10.1093/eurheartj/ehaa231.

107. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Feb 18. pii:S2213-2600(20)30076-X.

108. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis, International Journal of Infectious Diseases (2020). doi:10.1016/j.ijid.2020.03.017.

109. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARSCoV2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 Feb 24. pii:S2213-2600(20)30079-5. doi:10.1016/S22132600(20)30079-5. [Epub ahead of print].

110. Zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People’s Hospital. Intensive Care Med 2020. doi:10.1007/s00134-020-05993-9.

111. Zheng Y, Ma Y, Zhang J, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 Mar 5. doi:10.1038/s41569-020-0360-5. [Epub ahead of print].

112. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-62. doi:10.1016/S0140-6736(20)30566-3.

113. Zhu ZW, Tang JJ, Chai XP, et al. Comparison of heart failure and 2019 novel coronavirus pneumonia in chest CT features and clinical characteristics. Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 4;48(0):E007. doi:10.3760/cma.j.cn112148-20200218-00093. [Epub ahead of print].